Atrasentan for IgA Nephropathy

(ADVANCE Trial)

This trial aims to test atrasentan, a medication under study for treating IgA nephropathy (a kidney disease) in children and adolescents. Researchers seek to determine if this treatment can improve kidney health by reducing protein levels in urine, a sign of this condition. Participants will take atrasentan in a weight-adjusted dose over 104 weeks. The trial seeks children and teens who have had a kidney biopsy confirming IgA nephropathy, experience high protein levels in their urine despite current treatment, and maintain a stable medication regimen. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants a chance to contribute to potentially groundbreaking treatment advancements.

Participants must continue taking their current medications, such as ACE inhibitors or ARBs, at a stable dose for at least 120 days before starting the study treatment. If you are taking other medications like diuretics or antihypertensives, those doses should also be stable for the same period.

A previous study showed that atrasentan lowered protein levels in urine after 36 weeks of treatment without major safety issues. Another study found that patients with IgA nephropathy tolerated atrasentan well. Some patients experienced fluid retention, but there were no reports of serious heart problems or severe swelling. Overall, atrasentan appears safe for patients, with no new safety concerns reported.¹²³⁴⁵

Atrasentan is unique because it targets the endothelin A receptor, which plays a role in kidney damage associated with IgA nephropathy. Unlike current treatments that mainly focus on controlling blood pressure and reducing protein in urine, such as ACE inhibitors or ARBs, atrasentan directly interferes with the pathways leading to kidney inflammation and scarring. Researchers are excited about atrasentan because it has the potential to provide more targeted protection for kidney function and slow disease progression more effectively than existing treatments.

Research has shown that atrasentan can significantly reduce protein in the urine for patients with IgA nephropathy (IgAN), a condition marked by excessive protein in the urine. One study found that after nine months of treatment, patients had 36% less protein in their urine compared to those on a placebo. Another study supported these findings, showing a similar reduction in urine protein levels. Additionally, atrasentan has helped maintain kidney function over time. In this trial, participants will receive atrasentan in different cohorts based on body weight to evaluate its effectiveness in reducing protein loss in urine and protecting kidney health. These results suggest that atrasentan could be an effective treatment for IgAN.¹²³⁶⁷